Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· Phase 1/2· Bristol-Myers Squibb· Source
Contact: Yasser Ged, Site 0134
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· Phase 1/2· Pfizer· Source
Recruiting
Pediatric Radiation Therapy Registry
NCT07129317· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Contact: Ethan Arnone, BS
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Jean Hoffman-Censits, Site 0250
Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT07000084· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Max Kates (principal investigator)
Recruiting
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT06724237· Phase 3· Eastern Cooperative Oncology Group· Source
Contact: Cole H. Sterling (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Adel Mandl (principal investigator)
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Kristen Marrone (principal investigator)
Recruiting
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
NCT06796543· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Contact: Sahaja Acharya, MD
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544· Phase 1/2· Tango Therapeutics, Inc.· Source
Contact: Solmaz Sahebjam, MD (principal investigator)
Recruiting
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT06500481· Phase 3· NRG Oncology· Source
Contact: Carmen Kut (principal investigator)
Recruiting
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
NCT06376669· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Contact: Sherif Shaaban
Recruiting
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
NCT06525571· Phase 3· Johns Hopkins University· Source
Contact: Domani Rodriguez
Recruiting
Study in Patients With Breast Cancer Leptomeningeal Metastasis
NCT06638294· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Contact: Azka Tariq
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Nina D. Wagner-Johnston (principal investigator)
Recruiting
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116· Abramson Cancer Center at Penn Medicine· Source
Contact: Stephanie Grunwald
Active, not recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515· Phase 1· Eli Lilly and Company· Source
Recruiting
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05896839· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Evan J. Lipson (principal investigator)
Active, not recruiting
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662· Phase 1· Pfizer· Source
Recruiting
Pre-operative Hypofractionated Proton Therapy
NCT05917301· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Contact: Curtiland Deville, MD
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Jean H. Hoffman-Censits (principal investigator)
Recruiting
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
NCT05780814· Johns Hopkins University· Source
Contact: Katie Smith, BA
Active, not recruiting
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Kristen Marrone (principal investigator)
Active, not recruiting
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
NCT05977907· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Recruiting
Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
NCT05792722· Johns Hopkins University· Source
Contact: Armine Smith, MD
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Jennifer Y. Sheng (principal investigator)
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Eric D. Miller, MD, PhD
Recruiting
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
NCT05658731· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Contact: Sahaja Acharya, MD
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924· Phase 1/2· Institut de Recherches Internationales Servier· Source
Contact: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Recruiting
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
NCT05672615· Johns Hopkins University· Source
Contact: Domani Rodriguez
Recruiting
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
NCT05768919· Phase 1/2· SignPath Pharma, Inc.· Source
Contact: Michelle Comas
Active, not recruiting
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial
NCT05247905· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Recruiting
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Katherine M. Bever (principal investigator)
Recruiting
Gender Related Coping and Survivorship for Genitourinary Cancers
NCT05649306· Johns Hopkins University· Source
Contact: Riziki Covington
Active, not recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
NCT05318573· Phase 2· Fujifilm Pharmaceuticals U.S.A., Inc.· Source
Active, not recruiting
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
NCT05121545· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Recruiting
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04628767· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Jean H. Hoffman-Censits (principal investigator)
Active, not recruiting
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209· Phase 2· Massachusetts General Hospital· Source
Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334· Phase 2· National Cancer Institute (NCI)· Source
Contact: Michael J. Pishvaian (principal investigator)
Active, not recruiting
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
NCT04216290· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· Phase 3· National Cancer Institute (NCI)· Source
Contact: Nina D. Wagner-Johnston (principal investigator)
Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Sarah Waheed (principal investigator)
Active, not recruiting
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
NCT04548752· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT04443348· Phase 2· Laura M. Spring, MD· Source
Showing 50 of 98.